Overview:
Hormone receptor–positive/HER2-negative metastatic breast cancer remains the most common subtype of advanced breast cancer, yet treatment selection is becoming increasingly complex as the therapeutic landscape rapidly evolves. Advances in oral selective estrogen receptor degraders (SERDs), next-generation endocrine therapies, and biomarker-informed targeted combinations are reshaping expectations for endocrine sensitivity, resistance management, and sequencing strategies. As new clinical data emerge, clinicians must interpret efficacy, safety, and patient-selection considerations to optimize individualized care.
This online, CME-certified Oncology Town Hall Series: Oral
SERDs in HR+/HER2- Metastatic Breast Cancer - What the Latest Data Really Tell
Us will bring together expert faculty to review the key recent findings and
discuss their potential implications for current practice. Following the 2026
Annual European Oncology Congress on Breast Cancer in Berlin, the program will
feature dynamic discussions, practical insights, and the latest data from
pivotal clinical trials. The interactive format is designed to encourage
thoughtful exchange and provide actionable guidance for optimizing patient care.
Learning Objectives:
Upon completion of this activity, learners will be better prepared
to:
- Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer.
- Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC.
- Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC.
Target Audience:
This educational program is primarily directed toward a
global audience of medical oncologists, advanced practice providers, nurses and
other HCPs who are involved in the management of patients with advanced or
metastatic breast cancer.